Ilatreotide

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Description
Sources: Morton I.K. , Hall Judith M., Concise Dictionary of Pharmacological Agents: Properties and Synonyms, retrieved from: https://books.google.ru/books?id=mqaOMOtk61IC&pg=PA151&lpg=PA151&dq=ILATREOTIDE&source=bl&ots=T9qvUjCj3E&sig=ACfU3U3apx4pQA1jqsRc1PuiK0EsFa06Mg&hl=ru&sa=X&ved=2ahUKEwi48-iY2sXiAhWCqIsKHRanC6EQ6AEwBXoECAkQAQ#v=onepage&q=ILATREOTIDE&f=false

Ilatreotide was developed as a somatostatin receptor agonist with potential for treating gastroenteropancreatic tumors. It is an orally active pituitary and guts hormonal secretion inhibitor.

Approval Year

Patents

Patents

Substance Class	Protein Created by `admin` on `Mon Mar 31 20:53:53 GMT 2025` Edited by `admin` on `Mon Mar 31 20:53:53 GMT 2025`
Protein Type	RECEPTOR LIGAND
Protein Sub Type	SOMATOSTATIN PEPTIDES
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	398F0EG823
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SDZ CO 611

Preferred Name

English

Ilatreotide

Official Name

English

SDZ-CO-611

Code

English

Ilatreotide [INN]

Common Name

English

Code System Code Type Description

CAS

119719-11-8

Created by admin on Mon Mar 31 20:53:53 GMT 2025 , Edited by admin on Mon Mar 31 20:53:53 GMT 2025

PRIMARY

FDA UNII

398F0EG823

Created by admin on Mon Mar 31 20:53:53 GMT 2025 , Edited by admin on Mon Mar 31 20:53:53 GMT 2025

PRIMARY

NCI_THESAURUS

C166660

Created by admin on Mon Mar 31 20:53:53 GMT 2025 , Edited by admin on Mon Mar 31 20:53:53 GMT 2025

PRIMARY

EVMPD

SUB08129MIG

Created by admin on Mon Mar 31 20:53:53 GMT 2025 , Edited by admin on Mon Mar 31 20:53:53 GMT 2025

PRIMARY

INN

6862

Created by admin on Mon Mar 31 20:53:53 GMT 2025 , Edited by admin on Mon Mar 31 20:53:53 GMT 2025

PRIMARY

PUBCHEM

72046

Created by admin on Mon Mar 31 20:53:53 GMT 2025 , Edited by admin on Mon Mar 31 20:53:53 GMT 2025

PRIMARY

SMS_ID

100000083683

Created by admin on Mon Mar 31 20:53:53 GMT 2025 , Edited by admin on Mon Mar 31 20:53:53 GMT 2025

PRIMARY

ChEMBL

CHEMBL2104390

Created by admin on Mon Mar 31 20:53:53 GMT 2025 , Edited by admin on Mon Mar 31 20:53:53 GMT 2025

PRIMARY

From	To
1_2	1_7

Related Record Type Details


					NQX9KB6PCL

TARGET->INHIBITOR OF RELEASE

Amount:


					8X85ZJG6XJ

SOMATOSTATIN RECEPTOR TYPE 5

TARGET -> AGONIST

Amount:


					D73QL0OMU2

SOMATOSTATIN RECEPTOR TYPE 2

TARGET -> AGONIST

Amount:


					6E20216Q0L

PARENT -> DERIVATIVE

Amount:

Related Record Type Details


					398F0EG823

ACTIVE MOIETY

Comments:

Has about 10 times higher oral effect bioavailability than octreotide while maintaining the selectivity, metabolic stability and long duration of action of the parent compound.

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO ACID SUBSTITUTION	[1_8]		T		L-THREONINOL	A16V466XOD
AMINO ACID SUBSTITUTION	[1_1]		f		D-PHENYLALANINE-.BETA.-MALTULOSE	7XD9EN3A7B

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Molecular Formula	CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL